Items Tagged ‘inhibitor’

June 8th, 2016

Tecentriq® Approved for Bladder Cancer

By

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is […]

View full entry

Tags: atezolizumab, Bladder Cancer, inhibitor, News, PD-1, PD-L1, Stage IV/Metastatic Bladder Cancer, Tecentriq, urothelial carcinoma